Use in patients with MASH of drugs that have demonstrated in clinical trials the ability to reduce MASH and/or regress liver fibrosis: Pioglitazone, Vitamin E, GLP-1 analogs (semaglutide and liraglutide),GLP-1/GIP analogues (thirzepatide). This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.